Ultraprocessed Food Increases Disease Burden in UC Ultraprocessed Food Increases Disease Burden in UC
Dietary strategies for patients with ulcerative colitis should focus on boosting the consumption of unprocessed or minimally processed foods.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 27, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
Mirikizumab Offers Durable Response Up to 2 Years in UC Mirikizumab Offers Durable Response Up to 2 Years in UC
A long-term maintenance study suggested continuing mirikizumab for 104 weeks is safe and provides durable benefit in patients with active ulcerative colitis.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 27, 2024 Category: Drugs & Pharmacology Tags: Gastroenterology Source Type: news
Nightshade Vegetables Aren ’ t Actually Bad for You
If you’ve ever gone down the rabbit hole of health and wellness trends online, you’ve likely stumbled upon the so-called shadowy side of nightshades—vegetables that include tomatoes, potatoes, eggplants, and peppers. What’s made them suddenly newsworthy is that they’ve been singled out by self-proclaimed wellness experts and celebrity dieters as culprits behind a range of health issues, from arthritis to autoimmune disease flare-ups and indigestion.
While there’s little scientific evidence for these claims, some people report feeling better after cutting nightshades from their diets. ...
Source: TIME: Health - March 26, 2024 Category: Consumer Health News Authors: Claire Sibonney Tags: Uncategorized Evergreen freelance healthscienceclimate Source Type: news
How COVID-19 Treatments Affect Patients With IBD How COVID-19 Treatments Affect Patients With IBD
Inflammatory bowel disease therapies for patients may need to be briefly halted during treatment for COVID-19, but it does not increase flares.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 26, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
US Insurers Out of Step With IBD Treatment Guidelines US Insurers Out of Step With IBD Treatment Guidelines
Most US insurance companies require patients to fail conventional therapies for Crohn ' s disease and ulcerative colitis before they will cover a biologic agent, contrary to treatment guidelines.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 14, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
Sun Pharma recalls around 55k bottles of generic medication in US
Sun Pharma is recalling approximately 55,000 bottles of a generic medication used to treat bowel disease in the US market. The recall is due to "Failed Dissolution Specifications," according to the US Food & Drug Administration (USFDA). The affected Mesalamine extended-release capsules were manufactured at Sun Pharma's Mohali plant and distributed in the US by Sun Pharmaceutical Industries Inc. Mesalamine capsules are indicated for treating mild to moderate ulcerative colitis. The US generic drug market was valued at around USD 115.2 billion in 2019, with Sun Pharma being a major player in the market. (Source: The Econ...
Source: The Economic Times Healthcare and Biotech News - March 8, 2024 Category: Pharmaceuticals Source Type: news
Top-Down Treatment Superior for Crohn Disease
TUESDAY, March 5, 2024 -- Top-down treatment for Crohn disease (combination infliximab plus immunomodulator) achieves substantially better outcomes than accelerated step-up treatment, according to a study published online Feb. 22 in The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 5, 2024 Category: Pharmaceuticals Source Type: news
Vedolizumab Shows Greater Persistence Than Tofacitinib in UC Vedolizumab Shows Greater Persistence Than Tofacitinib in UC
Vedolizumab had greater treatment persistence than tofacitinib in a retrospective study of patients with ulcerative colitis (UC) who were previously bio-naive.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 28, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
Novel Biotherapeutic to Be Tested in Ulcerative Colitis Novel Biotherapeutic to Be Tested in Ulcerative Colitis
An investigational combination of eight strains of bacteria known collectively as MB310 — a live biotherapeutic product — is due to start its first clinical trial in ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 26, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
Risankizumab Beats Ustekinumab for Previously Treated Crohn's
(MedPage Today) -- Risankizumab (Skyrizi) resulted in more clinical remissions compared with ustekinumab (Stelara) in adults with moderate to severe Crohn's disease who had failed at least one previous tumor necrosis factor (TNF) inhibitor, the... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 26, 2024 Category: Gastroenterology Source Type: news
AI-Identified Vascular Healing Can Predict Relapse in UC AI-Identified Vascular Healing Can Predict Relapse in UC
An AI-assisted image-enhanced endoscopy system accurately assessed vascular healing and predicted clinical relapse in patients with ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 26, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
Top-Down Treatment Superior to Step-Up Approach for Crohn's Disease
(MedPage Today) -- Early and aggressive immunosuppressive therapy with tumor necrosis factor (TNF) inhibitors significantly outperformed conventional therapy for patients with newly diagnosed Crohn's disease and should become the standard for most... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 26, 2024 Category: Gastroenterology Source Type: news
Treating Crohn's Sooner, More Aggressively Greatly Improves Outcomes: Study
MONDAY, Feb. 26, 2024 -- In a finding that suggests sooner is better than later, a new trial shows that giving advanced treatment early to Crohn ’s patients can dramatically improve their gut health.About 80% of those who got therapy with an... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 26, 2024 Category: General Medicine Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Investor Update - February 25, 2024 Category: Pharmaceuticals Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Media News - February 25, 2024 Category: Pharmaceuticals Source Type: news
